How to read this list
Not all evidence is equal, so we group it by kind.
- Reference fact sheets come from US government health agencies. They summarize what is well established about a nutrient.
- Expert advisories and reviews pull together many studies. They are the best summary of a young field, but they can only be as strong as the studies behind them.
- Case reports describe a few individual patients. They can raise a warning, but they cannot tell you how common something is or prove what caused it.
Reference fact sheets
- Thiamin: Fact Sheet for Health Professionals, NIH Office of Dietary Supplements. Body stores and half life, daily needs, food sources, cooking losses, groups at risk, the absence of an upper limit, and medicines that lower thiamine.
- Thiamin: Fact Sheet for Consumers, NIH Office of Dietary Supplements. What thiamine does, in plain words. Most people in the United States get enough, and deficiency is rare.
- Thiamin, MedlinePlus Medical Encyclopedia, National Library of Medicine. Thiamine helps cells turn carbohydrates into energy and plays a role in nerve signals and muscle contraction.
Nutrition during GLP-1 treatment
- Nutritional priorities to support GLP-1 therapy for obesity, joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. Mozaffarian and colleagues, Obesity, 2025. Calorie intake drops 16 to 39 percent; plan for nutrient adequacy; consider tailored supplements such as vitamin D, calcium, B12 or a multivitamin.
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity, Simancas-Racines and colleagues, Obesity Pillars, 2026. Iron, B12, vitamin D, calcium, magnesium and zinc carry the strongest signals; thiamine is a context dependent concern tied to long vomiting or very low intake.
- Macronutrient, micronutrient supplementation and monitoring for patients on GLP-1 agonists, Sibal and colleagues, Nutrients, 2025. Observational data showed deficiencies within 12 months, most often vitamin D, followed by thiamine and other B vitamins.
- Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, Singhani and colleagues, Nutrition in Clinical Practice, 2026. Nausea, vomiting, diarrhea and constipation affect roughly 30 to 50 percent of patients, mostly early in treatment and after dose increases.
Case reports
- Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence, Bidesie and Oudman, Obesity, 2026. Six published cases of serious thiamine deficiency, all after long stomach symptoms and substantial weight loss. Read our summary in reports of low thiamine on GLP-1 medication.
What we use them for
The two guides that tie these together are vitamin B1 on GLP-1 medication and eating less on GLP-1 medication. How we pick and check sources is on our approach.
Found a source we got wrong, or one we should read? Tell us. We would rather fix a page than defend it.
The short list
Start with these three.
If you only read three sources, read these. They cover what thiamine does, what changes on GLP-1 medication, and how strong the evidence is.
- Thiamin: Fact Sheet for Health ProfessionalsNIH Office of Dietary Supplements. The reference for everything about thiamine itself.
- Nutritional priorities to support GLP-1 therapy for obesityJoint advisory, Obesity, 2025. What nutrition experts recommend during GLP-1 treatment.
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesityReview, Obesity Pillars, 2026. Where thiamine ranks among the nutrients at risk.